A biotech developing medicines to fix the faulty protein behind cystic fibrosis, aiming to restore normal lung function for patients.
No revenue yet; burning cash with net losses of USD 0.08B in 2025 and USD 0.06B in 2024, funded by investors until a drug succeeds.
Potential patent protection on novel CFTR correctors could create a niche, but Vertex Pharmaceuticals dominates cystic fibrosis with established therapies, making any moat unproven and weak.
Key events, in time order
Company confirms no further development of SION-719, names SION-451+SION-2222 as preferred combo; Phase 1 data met safety/exposure goals; Q2 cash ~$268.3M.
None yet
None yet
Discussion heat is rising, but there are not enough posts yet to summarize. You can open the market-wide stock page.
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
